JRNYS Review
Best for: Insured members wanting branded GLP-1s plus coaching at low medication cost
JRNYS is a telehealth weight-loss program built around branded GLP-1 medications, including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), dulaglutide, and liraglutide (Saxenda), paired with 1-on-1 coaching. Membership runs $89 to $169 per month depending on coaching level; for members with commercial insurance, GLP-1 cost should be capped around $25/month after any deductible. Self-pay options exist, with pricing confirmed after a provider consult. Care is led by CMO Dr. Henry Legere. JRNYS notes these drugs are diabetes-indicated and may be used off-label for weight loss.
Medium confidence · Last verified 2026-06-04 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
JRNYS is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
JRNYS prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Membership (basic) | brand | $89 |
| Membership (full coaching) | brand | $169 |
✓ Pros
- •Branded GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda)
- •Insured members may pay ~$25/mo for medication after deductible
- •Includes 1-on-1 coaching at every membership tier
- •Led by CMO Dr. Henry Legere with strong academic credentials
- •Transparent membership pricing ($89-$169/mo)
✗ Cons
- •Medication cost separate from membership; self-pay varies
- •Best value requires commercial insurance coverage
- •Compounded option not disclosed; brand-focused
- •State availability not published
Ready to start with JRNYS?
Starting at $89/month. See current pricing and start your free consultation.
Sources & methodology
Our JRNYS review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to JRNYS
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with JRNYS?
Starting at $89/month. See current pricing and start your free consultation.